secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001493152-23-038998
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals receives Nasdaq bid-price deficiency notice; 180 days to cure
----------------------------------------------------------------------------

- Received Nasdaq notice on Oct 30, 2023 for failing $1.00 minimum bid price for 30 consecutive business days.
- Has until April 29, 2024 to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not cured, may qualify for a second 180-day cure period if other listing criteria are met.
- Company plans to monitor bid price and may consider a reverse stock split to regain compliance.
- No immediate impact on Nasdaq listing; delisting risk if deficiency not cured within timelines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315223038998/0001493152-23-038998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315223038998/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer